Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg(Yale University), Abhijit A. Patel(Yale University), Nicholas Carriero(Yale University), Roy S. Herbst(Smilow Cancer Hospital), Nitin Sukumar, Yanhong Deng(Sun Yat-sen University), Azeet Narayan(Yale University), Daniel Zelterman(Yale University), Shrikant Mane(Yale Cancer Center), Jimmitti Teysir(Yale University), Katerina Politi(Yale Cancer Center), Scott Gettinger(Yale Cancer Center), Adam J. Kole(Yale University), Angela Lee, Sameer K. Nath(University of California San Diego), Lynn D. Wilson(The University of Texas MD Anderson Cancer Center), Roxanne Nemati(Yale University), Daniel J. Boffa(Yale University), Roy H. Decker(Yale University)
Cited by 456
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k